DUBLIN, April 27, 2022 /PRNewswire/ — The “Next Generation Gynecological Cancer Diagnostics Market – A Global Market and Regional Analysis: Focus on Technology, Product Type, End-User and Country Analysis – Analysis and Forecast, 2020-2031” report has been added to from ResearchAndMarkets.com offer.

In 2020, the Global Next Generation Gynecological Cancer Diagnostics Market was valued at $1,976.5 millionwho should reach $5,657.7 million by 2031, growing at a CAGR of 10.07% over the forecast period 2021-2031.

The purpose of this study is to obtain a comprehensive view of the Next Generation Gynecological Cancer Diagnostics market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements in the market. The study defines products and services used for next-generation gynecological cancer diagnosis to improve women’s prognosis and quality of life.

Molecular mutation profiling is essential for the identification and characterization of unique mutations to facilitate disease manifestation and progression. Comprehensive profiling of biological samples, especially blood and tissue, can help researchers and clinicians identify specific biomarkers that signify a particular disease.

The study aims to decipher the potential of next-generation gynecological cancer diagnostics in the field of research and diagnostics and its pivotal role in empowering the current genomic era to enable personalized medicine in routine care settings. .

The report includes an in-depth review of the major players and recent developments that have occurred in this market. Additionally, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis.

It also aims to address various aspects of the Global Next Generation Gynecological Cancer Diagnostics Market with the help of key factors driving the market, restraints, and challenges that may inhibit the overall market growth and current growth opportunities that will shape the future trajectory of market expansion.

In the research report, the market has been segmented into “product type”, “technology”, “indication”, “end user” and “regions”. Each of these segments covers market revenue inclination, underlying patterns, market snapshot over the projected years, and trends using analytics on primary and secondary data obtained.

Competitive landscape

The global market for next-generation gynecological cancer diagnostics is currently booming due to the presence of various juggernauts such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc. , BGI and PerkinElmer. Inc., as well as other medium and small medium enterprises, which provide a wide range of next-generation gynecological cancer diagnostic products and services to the market.

Several companies are trying to enter the market and stay competitive by adopting different strategies ranging from partnerships and collaborations to business expansions and product launches.

Main topics covered:

1 Definition

2 Scope of research

2.1 Key questions answered by the report

3 Research methodology

3.1 Global Next Generation Gynecological Cancer Diagnostics Market: Research Methodology

3.2 Data sources

3.3 Market estimation model

3.4 Business profiling criteria

4 Market

4.1 Presentation

4.2 Molecular profiling and techniques

4.3 Role of molecular diagnostics in gynecological cancers

4.4 Chronology of diagnostic technologies and regulatory benchmarks in gynecological cancers

4.5 Emerging molecular tests in gynecological cancer

4.6 Current Market Size and Growth Potential, USD Million, 2021-2031

5 Role of biomarkers in gynecological cancer

5.1 Presentation

5.2 Predictive molecular tests in gynecological cancer

5.3 Companion Diagnostics (CDx)

6 Impact of COVID-19 on the Global Next Generation Gynecological Cancer Diagnostics Market

6.1 Impact on supply chain and operations

6.2 Impact of COVID-19: Global Next Generation Gynecological Cancer Diagnostics Market

6.3 Pre- and post-COVID-19 impact assessment

7 Market dynamics

7.1 Overview

7.2 Impact analysis

7.3 Market Drivers

7.3.1 Further decline in the cost of next-generation sequencing (NGS)

7.3.2 Increase in Recommendations from Governmental Organizations and Scientific Societies

7.3.3 Increased Awareness and Transition to Personalized Medicine

7.4 Market Constraints

7.4.1 Next Generation Sequencing (NGS) Tests Approved by the Limited Food and Drug Administration (FDA)

7.4.2 Complexities related to the overall Next Generation Sequencing (NGS) process and the interpretation of results

7.4.3 Reimbursement challenges in countries

7.5 Market Opportunities

7.5.1 Increased market investment and government-funded projects

7.5.2 Acceptance of next generation sequencing (NGS) by emerging countries

8 Industry Outlook

8.1 Overview

8.2 Legal requirements and framework in the United States

8.2.1 FDA regulations

8.2.2 CMS regulations

8.3 Legal requirements and framework in Europe

8.4 Legal requirements and framework in Asia Pacific

8.4.1 China

8.4.2 Japan

8.5 Refund Scenario

8.6 Funding Scenario

9 Market Segmentation

9.1 Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), USD Million, 2020-2031

9.1.1 Overview

9.1.1.1 Polymerase chain reaction (PCR)

9.1.1.1.1 by value

9.1.1.1.2 by volume

9.1.1.2 Next Generation Sequencing (NGS)

9.1.1.2.1 by value

9.1.1.2.2 by volumes

9.1.1.2.3 Wide panels

9.1.1.2.4 Targeted gene panels

9.1.1.2.5 Single gene panels

9.1.1.3 Other technologies

10 Global Next Generation Gynecological Cancer Diagnostics Market (by Product Type), USD Million, 2020-2031

10.1 Overview

10.2 Services

10.3 Products

11 Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), USD Million, 2020-2031

11.1 Overview

11.2 Ovarian cancer

11.3 Cervical cancer

11.4 Uterine cancer

12 Global Next Generation Gynecological Cancer Diagnostics Market (by End User), USD Million, 2020-2031

12.1 Overview

12.2 Academic and research institutes

12.3 Hospitals and outpatient centers

12.4 Diagnostic Laboratories

12.5 Other end users

13 Global Next Generation Gynecological Cancer Diagnostics Market (by Region), USD Million, 2020-2031

13.1 Overview

13.2 North America

13.2.1 United States

13.2.2 Canada

13.3 Europe

13.3.1 Germany

13.3.2 United Kingdom

13.3.3 France

13.3.4 Italy

13.3.5 Spain

13.3.6 Netherlands

13.3.7 Rest ofEurope

13.4 Asia Pacific

13.4.1 China

13.4.2 Japan

13.4.3 India

13.4.4 Australia

13.4.5 South Korea

13.4.6 Rest ofAsia Pacific

13.5 Latin America

13.5.1 Brazil

13.5.2 Mexico

13.5.3 Rest ofLatin America

13.6 Rest of the world (right of way)

14 Competitive Landscape and Company Profiles

14.1 Competitive Landscape

14.2 Regulatory and legal activities

14.3 Synergistic Activities

14.4 Mergers and Acquisitions

14.5 Product launches

14.6 Business expansions

14.7 Market Share Analysis, by Service Providers, 2020

14.8 Market Share Analysis, By Product Manufacturers, 2020

14.9 Growth Share Analysis, by Company, 2019-2020

15 company profiles

• Agilent Technologies, Inc.
• ARUP Laboratories
• BGI Genomics
• CENTOGENE SA
• F. Hoffmann-La Roche SA
• Fulgent Genetics, Inc.
• Illumina, Inc.
• Invitee Corporation
• Konica Minolta, Inc.
• Laboratory Corporation of America Holdings
• Myriad Genetics, Inc.
• OPKO Health, Inc.
• QIAGEN AG
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.

For more information on this report, visit https://www.researchandmarkets.com/r/wzt7nh

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets